{"id":358,"date":"2026-02-06T16:34:45","date_gmt":"2026-02-06T16:34:45","guid":{"rendered":"https:\/\/event.eortc.org\/ena2026\/?page_id=358"},"modified":"2026-10-27T10:18:42","modified_gmt":"2026-10-27T10:18:42","slug":"late-breaking-abstracts","status":"publish","type":"page","link":"https:\/\/event.eortc.org\/ena2026\/late-breaking-abstracts\/","title":{"rendered":"Late breaking abstracts"},"content":{"rendered":"

<\/div><\/div><\/div><\/div>

Late-breaking abstracts<\/h2><\/div>

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Symposium.<\/p>\n

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumor activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel cancer biology with therapeutic implications \u2013 in each case the results should not have been fully available by the regular abstract submission deadline.<\/p>\n<\/div>

SUBMIT YOUR LBA<\/span><\/a><\/div>
LBA SUBMISSION POLICY<\/span><\/a><\/div>